- Home
- RZLT
RZLT
Rezolute Inc. (NV)
as 07-26-2024 4:00pm EST
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 142.9M | IPO Year: | N/A |
| Target Price: | $10.14 | AVG Volume (30 days): | 277.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.72 - $6.10 | Next Earning Date: | 09-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Rezolute Inc. (NV) (RZLT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | RZLT | Director | Jun 25 '24 | Buy | $4.15 | 4,815 | $19,982.25 | 37,508 | SEC Form 4 |
| Evans Daron | RZLT | CFO | Jun 14 '24 | Buy | $4.04 | 40,000 | $161,568.00 | 40,000 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Jun 14 '24 | Buy | $3.97 | 300 | $1,190.97 | 1,376 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Jun 14 '24 | Buy | $3.91 | 3,000 | $11,724.60 | 13,000 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Jun 14 '24 | Buy | $3.96 | 300 | $1,188.00 | 54,352 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Jun 14 '24 | Buy | $3.91 | 4,000 | $15,639.60 | 54,052 | SEC Form 4 |
| Evans Daron | RZLT | CFO | May 29 '24 | Buy | $3.50 | 451 | $1,578.50 | 121,351 | SEC Form 4 |
| Evans Daron | RZLT | CFO | May 23 '24 | Buy | $3.23 | 2,942 | $9,502.66 | 13,000 | SEC Form 4 |
| Evans Daron | RZLT | CFO | May 23 '24 | Buy | $2.85 | 58 | $165.30 | 10,058 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | May 23 '24 | Buy | $2.72 | 1,500 | $4,080.00 | 44,052 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | May 23 '24 | Buy | $2.68 | 6,000 | $16,057.80 | 50,052 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Mar 28 '24 | Buy | $2.55 | 500 | $1,275.00 | 1,076 | SEC Form 4 |
| Evans Daron | RZLT | CFO | Mar 15 '24 | Buy | $1.69 | 20,000 | $33,830.00 | 20,000 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Mar 14 '24 | Buy | $1.88 | 10,000 | $18,800.00 | 10,000 | SEC Form 4 |
| Evans Daron | RZLT | CFO | Mar 8 '24 | Buy | $1.93 | 50,000 | $96,345.00 | 120,900 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Mar 7 '24 | Buy | $1.85 | 500 | $925.00 | 576 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Mar 7 '24 | Buy | $1.85 | 500 | $925.00 | 500 | SEC Form 4 |
| Elam Nevan C | RZLT | CEO | Feb 26 '24 | Buy | $1.68 | 5,000 | $8,400.00 | 7,817 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Feb 23 '24 | Buy | $1.69 | 6,000 | $10,140.00 | 40,552 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Feb 23 '24 | Buy | $1.70 | 2,000 | $3,400.00 | 42,552 | SEC Form 4 |
| ROBERTS BRIAN KENNETH | RZLT | Chief Medical Officer | Feb 16 '24 | Buy | $1.31 | 7,000 | $9,142.00 | 34,552 | SEC Form 4 |
| Evans Daron | RZLT | CFO | Feb 16 '24 | Buy | $1.30 | 41,900 | $54,411.34 | 70,900 | SEC Form 4 |
| Evans Daron | RZLT | CFO | Feb 16 '24 | Buy | $1.37 | 4,500 | $6,165.00 | 4,500 | SEC Form 4 |
| Evans Daron | RZLT | CFO | Feb 16 '24 | Buy | $1.37 | 4,500 | $6,165.00 | 4,500 | SEC Form 4 |
| Kim Young-Jin | RZLT | Director | Jul 22 '22 | Buy | $1.91 | 36,503 | $69,859.44 | 115,450 | SEC Form 4 |
Latest Rezolute Inc. (NV) News
RZLT Breaking Stock News: Dive into RZLT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
GlobeNewswire
a month ago
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
GlobeNewswire
a month ago
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
GlobeNewswire
a month ago
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Newsfile
2 months ago
Edge Total Intelligence Inc. Updates Status of MCTO
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
GlobeNewswire
2 months ago
LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
Compare RZLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RZLT Rezolute Inc. (NV) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.